Literature DB >> 7373087

A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis.

Y J Bryson, C Monahan, M Pollack, W D Shields.   

Abstract

During a study of efficacy of amantadine prophylaxis of influenza A virus infection in young adults, gross and subtle side effects were monitored. Eighty-eight students were randomly selected to receive either amantadine or placebo for four weeks or both in a sequential crossover design of two weeks each. Side effects (i.e., dizziness, nervousness, and insomnia) occurred in 33% of those receiving amantadine and in 10% of those receiving placebo (P less than 0.005). Although side effects were well tolerated by most subjects, six volunteers discontinued amantadine because of marked complaints. Cessation of side effects occurred in more than half of those continuing amantadine. Sixteen students receiving amantadine had decreased performance on sustained attention tasks as compared with ones receiving placebo (P less than 0.05). Gross and subtle side effects of amantadine observed in this study on currently recommended dosage are higher than previously reported, which may be an important factor in consideration of mass prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7373087     DOI: 10.1093/infdis/141.5.543

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

Review 1.  Amantadine and rimantadine for influenza A in adults.

Authors:  T Jefferson; V Demicheli; C Di Pietrantonj; D Rivetti
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

2.  Amantadine for influenza A.

Authors:  K G Nicholson; M J Wiselka
Journal:  BMJ       Date:  1991-02-23

Review 3.  Amantadine for fatigue in multiple sclerosis.

Authors:  E Pucci; P Branãs; R D'Amico; G Giuliani; A Solari; C Taus
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine.

Authors:  S W Younkin; R F Betts; F K Roth; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

5.  Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine.

Authors:  V M Millet; M Dreisbach; Y J Bryson
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of amantadine hydrochloride.

Authors:  F Y Aoki; D S Sitar
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

7.  Anti-influenza A virus activity of amantadine hydrochloride and rimantadine hydrochloride in ferret tracheal ciliated epithelium.

Authors:  D B Burlington; G Meiklejohn; S R Mostow
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

8.  Serum concentrations and safety of rimantadine in paediatric patients.

Authors:  M C Nahata; M T Brady
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 9.  Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective.

Authors:  D R Guay
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

10.  Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults.

Authors:  F G Hayden; J M Gwaltney; R L Van de Castle; K F Adams; B Giordani
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.